Benefits of glioma resection in the corpus callosum

Forster, Marie-Thérèse; Behrens, Marion; Lortz, Irina; Conradi, Nadine; Senft, Christian; Voß, Martin; Rauch, Maximilian; Seifert, Volker

doi:10.1038/s41598-020-73928-x

Cited by 19 publications

(23 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, resection with low persistent neurological deficits and without long-term decline is possible. The use of neuronavigation and subcortical mapping might improve safety and outcomes 6 , 14 . Sughrue 20 described the key points in resecting of the anterior, the middle callosum, and the splenial bGBM.…”

Section: Discussionmentioning

confidence: 99%

“…Burks et al 21 presented evidence for the safe removal of anterior bGBM during awake brain surgery. Forster et al 6 concluded that the benefit of tumor resection might outweigh morbidity in patients with a preoperatively good neurological state. Moreover, the quality of life in patients who had a resection was improved compared with biopsy alone.…”

Section: Discussionmentioning

confidence: 99%

“…Due to unfavorable location and assumed poor risk-to-benefit ratio of resection, a biopsy is the preferred treatment option. However, there is growing evidence for the benefits of resection of these tumors 6 . Studies comparing survival time after resection versus biopsy alone in the management of bGBM are limited, often with small sample sizes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of surgical resection of butterfly glioblastoma on survival: a meta-analysis based on comparative studies

Chojak

Koźba-Gosztyła²,

Słychan

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Butterfly glioblastoma (bGBM) is a rare brain tumor that invades both hemispheres by crossing the corpus callosum. bGBM is associated with a dismal prognosis with a median survival time of a few months. Surgical resection is a rare treatment option due to the unfavorable location and assumed poor risk-to-benefit ratio. Therefore, a biopsy-alone approach is considered the main treatment option. This meta-analysis aimed to systematically evaluate whether resection of bGBM is associated with improved overall survival compared with biopsy alone. We searched three databases to find studies that compare resection with biopsy in 6-, 12- and 18-months overall survival in patients with bGBM. We calculated the pooled relative risk (RR) of mortality using a random-effects model. Five studies with 194 patients were included in the meta-analysis. Mortality was decreased for resection compared with biopsy at 6-months (RR 0.63 [95% CI 0.44–0.91]). No significant differences in overall survival were found at 12 (RR 0.76 [95% CI 0.50–1.14]) and 18-months (RR 0.84 [95% CI 0.56–1.26]). Surgical resection of bGBM is associated with an improved 6-months overall survival compared with biopsy alone. We have not found strong evidence supporting the superiority of resection over biopsy alone in overall survival at 12 and 18-months.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of surgical resection of butterfly glioblastoma on survival: a meta-analysis based on comparative studies

Chojak

Koźba-Gosztyła²,

Słychan

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…ccGlioma was also considered to have a higher incidence of PDGFRA alterations than non-ccGlioma in a previous study (Shen et al, 2020). Furthermore, ccGlioma was indicated to have a poorer prognosis than non-ccGlioma, and ccGBM had an even shorter median OS, ranging from 7.0 to 15.0 months after surgery (Dziurzynski et al, 2012;Chaichana et al, 2014;Chen et al, 2015;Burks et al, 2017;Dayani et al, 2018;Opoku-Darko et al, 2018;Forster et al, 2020;Franco et al, 2020). Therefore, we hypothesized that PDGFRA alterations may play an important role in GBM and lead to a higher incidence of CC invasion and a poorer prognosis.…”

Section: Comparison Of Ccgbm With Diffuse Midline Gliomamentioning

confidence: 94%

Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement

Cui

Gào

Chi³

et al. 2021

Front. Neurosci.

View full text Add to dashboard Cite

Purpose: To explore molecular alterations and their correlation with the survival of patients with glioblastoma (GBM) with corpus callosum (CC) involvement (ccGBM).Methods: Electronic medical records were reviewed for glioma patients tested for molecular alterations and treated at our hospital between January 2016 and July 2020. ccGBM was compared to GBM without CC involvement (non-ccGBM) to identify differences in molecular alterations. Clinical outcomes and survival were compared between ccGBM and non-ccGBM patients, as well as among patients with ccGBM with different molecular alteration statuses. ccGBM was also compared to diffuse midline glioma (DMG) to clarify their correlation in molecular alterations, the progression-free survival (PFS), and overall survival (OS).Results: Thirty ccGBM and 88 non-ccGBM patients were included. PDGFRA amplification (PDGFRAamp, 33.3 vs. 9.1%, P = 0.004) and missense mutation (PDGFRAmut, 20.0 vs. 3.4%, P = 0.011) both had higher incidences in ccGBM than in non-ccGBM. PDGFRA alteration was associated with the occurrence of ccGBM (OR = 4.91 [95% CI: 1.55–15.52], P = 0.007). ccGBM with PDGFRAamp resulted in a shorter median PFS (8.6 vs. 13.5 months, P = 0.025) and OS (12.4 vs. 17.9 months, P = 0.022) than non-ccGBM with PDGFRAnon-amp. ccGBM with PDGFRAamp combined with PDGFRAmut (PDGFRAamp-mut) had a shorter median PFS (7.6 vs. 8.9 months, P = 0.022) and OS (9.6 vs. 17.8 months, P = 0.006) than non-ccGBM with wild-type PDGFRA and no amplification (PDGFRA-w, non-amp). Compared to ccGBM with PDGFRA-w, non-amp, ccGBM with PDGFRAamp and PDGFRAamp-mut both had a shorter median PFS and OS (P < 0.05). The hazard ratios (HRs) of PDGFRAamp for PFS and OS in ccGBM were 3.08 (95% CI: 1.02–9.35, P = 0.047) and 5.07 (1.52–16.89, P = 0.008), respectively, and the HRs of PDGFRAamp-mut for PFS and OS were 13.16 (95% CI: 3.19–54.40, P < 0.001) and 16.36 (2.66–100.70, P = 0.003). ccGBM may have similar incidences of PDGFRAamp or mut (PDGFRAamp/mut) as DMG, and they also had similar median PFS (10.9 vs. 9.0 months, P = 0.558) and OS (16.8 vs. 11.5 months, P = 0.510).Conclusion:PDGFRA alterations are significantly associated with the occurrence and poor prognosis of ccGBM. ccGBM with PDGFRAamp/mut may be classified as a single subtype of GBM that has a similar survival rate to DMG. PDGFR inhibitors may be a promising treatment method for ccGBM.

show abstract

“…Post-operative MRIs were obtained within 72 h after surgery by a senior neuroradiologist to determine the extent of the resection ( 21 ). Gross total resection was defined as a resection without residual Gd-enhancement, whereas subtotal resection was considered any resection with residual Gd-enhancement and an extent of resection ≥90% ( 22 ).…”

Section: Methodsmentioning

confidence: 99%

Baseline Serum C-Reactive Protein and Plasma Fibrinogen-Based Score in the Prediction of Survival in Glioblastoma

et al. 2021

View full text Add to dashboard Cite

Objective: The present study investigates a score based on baseline C-reactive protein (CRP) and fibrinogen values (FC score) in 173 consecutive glioblastoma (GBM) patients.Methods: The optimal cut-off value for fibrinogen and CRP was defined as 3.5 g/dl and 3.0 mg/L, respectively, according to previous reports. Patients with elevated CRP and fibrinogen were classified with a score of 2, those with an elevation of only one of these parameters were allocated a score of 1, and those without any abnormalities were assigned a score of 0.Results: No significant differences in age, gender, tumor area, molecular pathology, physical status, or extent of resection were identified among the three groups defined by this score. Univariate survival analysis demonstrated that a high baseline FC score (≥1) is significantly associated with a shortened overall survival (OS) (HR: 1.52, 95% CI: 1.05–2.20, p = 0.027). A multivariate Cox regression analysis considering age (>65/≤65), extent of resection (GTR/STR), MGMT promoter status (hypermethylated/non-hypermethylated), and FC score (0/≥1) confirmed that an elevated FC score (≥1) is an independent predictor of shortened OS (HR: 1.71, 95% CI: 1.16–2.51, p = 0.006).Conclusions: The baseline fibrinogen and CRP score thus serves as an independent predictor of OS in GBM. Further investigations of the role of inflammation in the prediction of a prognosis are needed.

show abstract

Benefits of glioma resection in the corpus callosum

Cited by 19 publications

References 32 publications

Impact of surgical resection of butterfly glioblastoma on survival: a meta-analysis based on comparative studies

Impact of surgical resection of butterfly glioblastoma on survival: a meta-analysis based on comparative studies

Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement

Baseline Serum C-Reactive Protein and Plasma Fibrinogen-Based Score in the Prediction of Survival in Glioblastoma

Contact Info

Product

Resources

About